Home » Stocks » CYCN

Cyclerion Therapeutics, Inc. (CYCN)

Stock Price: $3.35 USD 0.11 (3.40%)
Updated Jul 28, 2021 4:00 PM EDT - Market closed
Market Cap 148.39M
Revenue (ttm) 1.34M
Net Income (ttm) -70.97M
Shares Out 40.42M
EPS (ttm) -2.22
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 28
Last Price $3.35
Previous Close $3.24
Change ($) 0.11
Change (%) 3.40%
Day's Open 3.29
Day's Range 3.18 - 3.38
Day's Volume 575,665
52-Week Range 2.08 - 8.96

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Research to be presented highlighting potential of neuropsychological biomarkers to guide the clinical development of Cyclerion's investigational therapeutics Research to be presented highlighting poten...

6 days ago - GlobeNewsWire

Cyclerion Therapeutics Inc (NASDAQ: CYCN) and Beacon Biosignals have expanded strategic partnerships between the two companies.  This collaboration is expected to identify disease-relevant biomarkers to...

2 weeks ago - Benzinga

BOSTON, July 8, 2021 /PRNewswire/ -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN) and Beacon Biosignals today announced an extended and expanded strategic partnership between the two companies.  This col...

2 weeks ago - PRNewsWire

Beacon Biosignals and Cyclerion to extend and expand partnership on data collection and analytics strategy to facilitate development of Cyclerion investigational therapeutics for neurological diseases a...

2 weeks ago - GlobeNewsWire

Which penny stocks on Reddit are you watching? Here's 4 for some watchlist inspiration The post Best Penny Stocks on Reddit to Buy?

Other stocks mentioned: BOXL, PLIN, VISL
1 month ago - PennyStocks

Meme penny stocks are heating up; are these 3 on your watchlist? The post Meme Penny Stocks Are Here to Stay; 3 For Your Summer Watchlist appeared first on Penny Stocks to Buy, Picks, News and Informati...

Other stocks mentioned: AGEN, MOSY
1 month ago - PennyStocks

Cyclerion Therapeutics Inc (NASDAQ: CYCN) has entered into an exclusive, global license agreement with Akebia Therapeutics Inc (NASDAQ: AKBA) for the development and commercialization of praliciguat. Un...

Other stocks mentioned: AKBA
1 month ago - Benzinga

Cyclerion eligible to receive up to $585 million in potential future development and commercial milestone payments, and tiered sales-based royalties

1 month ago - GlobeNewsWire

Proceeds to fund ongoing clinical development of CY6463 and advancement of next generation CY3018 program Proceeds to fund ongoing clinical development of CY6463 and advancement of next generation CY301...

1 month ago - GlobeNewsWire

Series of preclinical studies demonstrate the therapeutic potential of CY6463, a first-in-class, CNS-penetrant sGC stimulator

2 months ago - GlobeNewsWire

CAMBRIDGE, Mass., May 25, 2021 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN) today announced that Company management will present a corporate overview at the Jefferies Virtual Healthca...

2 months ago - GlobeNewsWire

After this week's market pullback, some of these penny stocks are trending into the weekend. The post Best Penny Stocks To Buy Right Now?

Other stocks mentioned: JAGX, KXIN
2 months ago - PennyStocks

Cyclerion Therapeutics, Inc. (NASDAQ: CYCN), Sol-Gel Technologies Ltd. (NASDAQ: SLGL), Aldeyra Therapeutics, Inc. (NASDAQ: ALDX), DermTech, Inc. (NASDAQ: DMTK) and Bionano Genomics, Inc. (NASDAQ: BNGO) ...

Other stocks mentioned: BNGO, DMTK, ALDX, SLGL
3 months ago - Benzinga

Provided updates on development strategy and execution for CY6463, a first-in-class, CNS-penetrant sGC stimulator, including IND clearance from FDA in ADv and ongoing MELAS program

3 months ago - GlobeNewsWire

Senior CNS expert and biotech business leader to inform strategy and future clinical development Senior CNS expert and biotech business leader to inform strategy and future clinical development

3 months ago - GlobeNewsWire

5 Penny Stocks To Watch For The Last Week Of April 2021 The post Best Penny Stocks To Buy Now? 5 For Your Watch List Next Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyS...

Other stocks mentioned: APTX, BLRX, LCTX, PTN
3 months ago - PennyStocks

CAMBRIDGE, Mass., April 21, 2021 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive fun...

3 months ago - GlobeNewsWire

Company to discuss clinical updates for CY6463, including Phase 2a studies in ADv and MELAS, and plans to initiate Phase 1b clinical trial in CIAS

3 months ago - GlobeNewsWire

CAMBRIDGE, Mass., March 18, 2021 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive fun...

4 months ago - GlobeNewsWire

Leading experts in central nervous system (CNS) clinical development and translational sciences to advise company's advancement of therapeutic pipeline candidates

6 months ago - GlobeNewsWire

CAMBRIDGE, Mass., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company developing innovative medicines for people with serious diseas...

6 months ago - GlobeNewsWire

Anjeza Gjino promoted to Chief Financial Officer; Bill Huyett to transition to Strategic Advisor

7 months ago - GlobeNewsWire

Positive IW-6463 translational pharmacology study in healthy elderly subjects showed significant i mprovements in multiple measures associated with age-related cognitive decline and neurodegenerative di...

8 months ago - GlobeNewsWire

A second midstage failure is hurting the biotech's stock price today.

9 months ago - The Motley Fool

Showed significant i mprovements in neurophysiological and objective performance measures associated with age-related cognitive decline and neurodegenerative diseases

9 months ago - GlobeNewsWire

Study results do not support further internal development Study results do not support further internal development

9 months ago - GlobeNewsWire

CAMBRIDGE, Mass., Sept. 04, 2020 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company focused on the development of soluble guanylate cyclase (sG...

10 months ago - GlobeNewsWire

CAMBRIDGE, Mass., Aug. 25, 2020 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company developing treatments for serious and orphan diseases, today...

11 months ago - GlobeNewsWire

-  IW-6463 and olinciguat top line clinical study results remain on track for late summer and late Q3 2020, respectively   -

11 months ago - GlobeNewsWire

 -  Additional capital to accelerate clinical development of IW-6463 in two CNS indications and olinciguat for sickle cell disease  -

11 months ago - GlobeNewsWire

CAMBRIDGE, Mass., July 17, 2020 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company developing treatments for serious and orphan diseases, today...

1 year ago - GlobeNewsWire

– Closed enrollment for olinciguat Phase 2 STRONG SCD study for sickle cell disease; topline data readout expected Q3 2020 –

1 year ago - GlobeNewsWire

– Management to review the Company's sGC clinical pipeline programs: praliciguat for diabetic nephropathy, olinciguat for sickle cell disease, and IW-6463 for neurodegenerative diseases –

1 year ago - GlobeNewsWire

The company evaluated praliciguat in 2 diseases, diabetic nephropathy and HFpEF, which are very complex and difficult-to-treat.

1 year ago - Forbes

A double clinical trial failure sends the biotech’s shares down.

1 year ago - The Motley Fool

Shares of Cyclerion Therapeutics Inc. plummeted 71% toward a record low Wednesday, to pace all premarket losers, after the biopharmaceutical company said a Phase 2 trial of its diabetes treatment missed...

1 year ago - Market Watch

About CYCN

Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its product candidates include CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase II trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS) and Alzheimer's disease with vascular pathology (ADv); Olinciguat, an orally administered vascular soluble guanylate cy... [Read more...]

Industry
Biotechnology
Stock Exchange
NASDAQ
Ticker Symbol
CYCN
Full Company Profile

Financial Performance

In 2020, CYCN's revenue was $2.30 million, a decrease of -49.06% compared to the previous year's $4.51 million. Losses were -$77.80 million, -36.75% less than in 2019.

Financial Statements

Analyst Forecasts

According to one analyst, the rating for CYCN stock is "Hold" and the 12-month stock price forecast is 4.00.

Price Target
$4.00
Analyst Consensus: Hold